PARP inhibition in ovarian cancer: state of the science

Gynecol Oncol. 2015 Jan;136(1):8-10. doi: 10.1016/j.ygyno.2014.12.009.

Authors

Camille C Gunderson¹, Kathleen N Moore²

Affiliations

¹ University of Oklahoma Health Sciences Center, Stephenson Cancer Center, 800 NE 10th Street, Suite 5040, Oklahoma City, Oklahoma 73104. Electronic address: camille-gunderson@ouhsc.edu.
² University of Oklahoma Health Sciences Center, Stephenson Cancer Center, 800 NE 10th Street, Suite 5040, Oklahoma City, Oklahoma 73104. Electronic address: kathleen-moore@ouhsc.edu.

PMID: 25554012
DOI: 10.1016/j.ygyno.2014.12.009

No abstract available

MeSH terms

Clinical Trials, Phase II as Topic
Enzyme Inhibitors / pharmacology
Enzyme Inhibitors / therapeutic use*
Female
Humans
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / enzymology*
Poly(ADP-ribose) Polymerase Inhibitors*
Randomized Controlled Trials as Topic

Substances

Enzyme Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors

Associated data

ClinicalTrials.gov/NCT01081951